Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group

Califano, Raffaele; Griffiths, Richard W.; Lorigan, Paul; Ashcroft, Linda; Taylor, Paul D.; Burt, Paul A; Lee, Lip W; Chittalia, A.; Harris, Maggie A; Faivre-Finn, Corinne; Thatcher, Nick; Blackhall, Fiona

doi:10.1016/j.lungcan.2011.01.001

Cited by 5 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analysis of these complex networks offers us meaningful insights into biological signaling pathways (Altay et al, 2011). Cellular and biological processes are, at the genetic level, quite complex and become significantly altered when healthy cells adopt a malignant phenotype (Califano et al, 2011;Emmert-Streib et al, 2012). A single gene can possess multiple functions, including the regulation of expression of different genes, which may contribute to disease progression.…”

Section: Introductionmentioning

confidence: 99%

Profiling of differentially expressed genes in cadmium-induced prostate carcinogenesis

Kolluru¹,

Tyagi²,

Chandrasekaran³

et al. 2019

Toxicology and Applied Pharmacology

View full text Add to dashboard Cite

The aim of the present study was to investigate the genetic signatures of cadmium-transformed prostate epithelial (CTPE) cells and to identify the potential molecular signaling involved in their malignant transformation. The dataset contained normal prostate epithelial (RWPE-1) and CTPE cells. To further examine the biological functions of the identified differentially expressed genes (DEGs), Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Reactome pathway enrichment analyses were performed. In total, 2,357 DEGs were identified, including 1,083 upregulated genes and 1,274 downregulated genes. GO, KEGG, and Reactome pathway enrichment analyses indicated that upregulated genes were significantly enriched in ECM-receptor, focal adhesion, TGFβ signaling, and syndecan interactions, while downregulated genes were mainly involved in cell cycle regulation, arachidonic acid metabolism, oxidative phosphorylation, and folate biosynthesis (p < 0.05). The top upregulated (SATB1 (p<0.0001), EYA2 (p<0.0001) and KPNA7 (p<0.0027)) and downregulated (PITX2 (p<0.0007), PDLIM4 (p<0.0020) and FABP5 (p<0.0007)) genes were further validated via qRT-PCR analysis. In conclusion, the present study profiled DEGs in RWPE-1 and CTPE cells and identified gene pathways that may be associated with malignant transformation and tumor progression.

show abstract

Section: Introductionmentioning

confidence: 99%

Profiling of differentially expressed genes in cadmium-induced prostate carcinogenesis

Kolluru¹,

Tyagi²,

Chandrasekaran³

et al. 2019

Toxicology and Applied Pharmacology

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that ECOG-PS = 2 is a poor prognostic factor for docetaxel alone or docetaxel plus ramucirumab therapy in previously treated patients with NSCLC. 25,26 We retrospectively demonstrated that a poor PS (ECOG-PS = 2) was an independent prognostic factor for PFS and OS in the second-line setting after chemoimmunotherapy. Therefore, the decision to use second-line therapy following chemoimmunotherapy for NSCLC patients with a poor PS should be made with caution.…”

Section: Discussionmentioning

confidence: 99%

Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study

et al. 2021

View full text Add to dashboard Cite

Background: Chemoimmunotherapy has become a standard treatment option for patients with untreated advanced non-small-cell lung cancer (NSCLC). However, numerous patients with advanced NSCLC develop disease progression. Therefore, the selection of second-line treatment after chemoimmunotherapy is crucial for improving clinical outcomes. Methods: Of 88 enrolled patients with advanced NSCLC who received chemoimmunotherapy, we retrospectively evaluated 33 who received second-line chemotherapy after progression of chemoimmunotherapy at six centers in Japan. Among them, 18 patients received docetaxel plus ramucirumab and 15 patients received single-agent chemotherapy.Results: The objective response rate in patients treated with docetaxel plus ramucirumab was significantly higher than that in patients treated with a single-agent chemotherapy regimen (55.6% vs. 0%, p < 0.001). The median progression-free survival (PFS) of patients who received docetaxel plus ramucirumab and single-agent chemotherapy was 5.8 months and 5.0 months, respectively (log-rank test p = 0.17). In the docetaxel plus ramucirumab regimen group, patients who responded to chemoimmunotherapy for ≥8.8 months had a significantly longer response to docetaxel plus ramucirumab than those who responded for <8.8 months (not reached vs. 4.1 months, log-rank test p = 0.003). In contrast, in the single-agent chemotherapy group, there was no significant difference in PFS between the ≥8.8and <8.8-month PFS groups with chemoimmunotherapy (5.0 vs. 1.6 months, log-rank test p = 0.66). Conclusion: Our retrospective observations suggest that the group with longer PFS with chemoimmunotherapy might be expected to benefit from docetaxel plus ramucirumab treatment in second-line settings for patients with advanced NSCLC.

show abstract

“…Although there are no reports on the efficacy of DOC plus RAM for patients with poor ECOG-PS, there are various reports about the efficacy and safety of DOC alone in ECOG-PS 2 patients. These studies have made its use controversial because of the significant increase in febrile neutropenia (23)(24)(25). Although the 2018 National Comprehensive Cancer Network Guidelines recommend DOC plus RAM treatment in previously treated patients with ECOG-PS 0-2 with NSCLC, ECOG-PS 2 patients were not included in the REVEL trial and there is no evidence that demonstrates the efficacy and safety in ECOG-PS 2 patients (26).…”

Section: Cmentioning

confidence: 99%

Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study

Matsumoto¹,

Tamiya²,

Matsuda³

et al. 2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: Docetaxel (DOC) plus ramucirumab (RAM) has been recommended as an optimal therapy for previously treated patients with non-small cell lung cancer (NSCLC). In a clinical setting, there are few reports about DOC plus RAM, therefore its effect on factors such as Eastern Cooperative Oncology Group (ECOG) performance status (PS) and metastatic sites is still unknown. Methods:We recruited NSCLC patients who received DOC plus RAM in four medical facilities in Japan from June 2016 to March 2020. We retrospectively investigated the overall response rate (ORR), disease control rate (DCR), and progression-free survival (PFS) of DOC plus RAM and conducted univariate and multivariate analyses using PFS as a dependent factor. Patients were followed up until June 30, 2020.

show abstract

Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group

Cited by 5 publications

References 33 publications

Profiling of differentially expressed genes in cadmium-induced prostate carcinogenesis

Profiling of differentially expressed genes in cadmium-induced prostate carcinogenesis

Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study

Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study

Contact Info

Product

Resources

About